U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 71 - 80 of 111 results

mixture
Status:
US Previously Marketed
First approved in 1953

Class:
MIXTURE

mixture
Status:
US Previously Marketed
Source:
Chloresium by Rystan
(1945)
Source URL:
First approved in 1945
Source:
Chloresium by Rystan
Source URL:

Class:
MIXTURE

Conditions:

Chlorophyll is a green pigment present in plants, as well as in eukaryotic single-celled algae and in several photosynthetic prokaryotes (the cyanobacteria and prochlorophytes), it plays crucial role in photosynthesis. The initial step in photosynthesis is the absorption of light by chlorophylls attached to proteins in the thylakoid membranes. Like cytochromes, chlorophylls consist of a porphyrin ring attached to a long hydrocarbon side chain. The energy of the absorbed light is used to remove electrons from an unwilling donor (water, in green plants), forming oxygen, and then to transfer the electrons to a primary electron acceptor, a quinone designated Q, which is similar to CoQ. Chlorophyll derivatives Radachlorin/Bremachlorin and Radachlorophyll/Bremachlorophyll are actually a second generation photosensitizer for photodynamic therapy of malignant and benign pathologies. Radachlorophyll/Bremachlorophyll may change blood lipids and pressure, including: (1) reduced total cholesterol; (2) increased HDL cholesterol; (3) reduced triglycerides; and (4) reduced systolic and diastolic blood pressure as well as immunomodulating properties. As a dietary supplement chlorophyll supports multiple body systems: provides antioxidant activity, supports vascular health, supports the body's normal immune system function, provides cardiovascular support, maintains skin and hair health. Chlorophylls (E140) is used as a food additive.
mixture
Status:
US Previously Marketed
Source:
Tyrothricin by Merck
(1942)
Source URL:
First approved in 1942
Source:
Tyrothricin by Merck
Source URL:

Class:
MIXTURE



Tyrothricin is a mixture of non-ribosomal peptides produced by Brevibacillus brevis, now known as Aneurinibacillus migulanus, a gram positive aerobic bacteria. The compound mixture shows activity against bacteria, fungi and some viruses. A very interesting feature of AMPs is the fact, that even in vitro it is almost impossible to induce resistances. It is a locally effective antibiotic effective against gram-positive bacteria. It is sometimes combined with benzocaine 5 mg (Tyrozets) to provide relief from sore throats. Recommended for short-term relief of symptoms of oral and throat inflammation. Prevention of infections before/during mouth and throat operations (tooth extractions, gum surgical treatment). Tyrothricin inhibits protein biosynthesis of gram-positive organisms, but is completely ineffective against gram-negative.
mixture
Status:
US Previously Marketed
Source:
Aloin U.S.P.
(1921)
Source URL:
First marketed in 1921

Class:
MIXTURE

mixture
Status:
Possibly Marketed Outside US
Source:
NCT03237182: Phase 4 Interventional Terminated Tuberculosis, Multidrug-Resistant
(2017)
Source URL:
First approved in 2022
Source:
Kanamycin Sulfates by KDG Impresa LLC, Aqion
Source URL:

Class:
MIXTURE



Kanamycin (a mixture of kanamycin A, B and C) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. It is effective against Gram-negative bacteria and certain Gram-positive bacteria. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Serious side effects include tinnitus or loss of hearing, toxicity to kidneys, and allergic reactions to the drug. Mixing of an aminoglycoside with beta-lactam-type antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
mixture
Status:
Possibly Marketed Outside US
Source:
part347
Source URL:

Class:
MIXTURE

mixture
Status:
Possibly Marketed Outside US
Source:
NCT04590521: Phase 4 Interventional Completed HPV Infection
(2022)
Source URL:

Class:
MIXTURE

mixture
Status:
Possibly Marketed Outside US
Source:
NCT03538327: Phase 4 Interventional Completed Hypertension
(2013)
Source URL:

Class:
MIXTURE

mixture
Status:
Possibly Marketed Outside US
Source:
SURMAX by Buzzetti, F. et al.
Source URL:

Class:
MIXTURE



Avilamycin is an orthosomycin antibiotic complex produced by the fermentation of Streptomyces viridochromogenes. Avilamycin is intended for use as a veterinary medicine in chickens, turkeys, pigs and rabbits to control bacterial enteric infections. It exhibits good antimicrobial activity against important veterinary Gram-positive pathogens (e.g., Clostridium perfringens) and has no related molecules in its class in human use. Therefore, avilamycin has been developed for treating necrotic enteritis in poultry, and enteric disease in pig and rabbits. Avilamycin inhibits bacterial protein synthesis through a novel mechanism of action by binding to the 50S ribosomal subunit and preventing the association of IF2, which inhibits the formation of the mature 70S initiation complex, and the correct positioning of tRNA in the aminoacyl site. No adverse drug-related changes were observed.